Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Lymphoblastic Leukemia Therapy
Studies from Stanford University further understanding of acute lymphoblastic leukemia therapy
April 11th, 2007
Investigators publish new data in the report "Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro. Human monoclonal antibody (mAb) 216 is a naturally occurring IgM cytotoxic mAb that binds to a glycosylated epitope on the surface of B-lymphocytes. This study investigated if this mAb could bind and kill acute lymphoblastic leukemia (ALL) B-progenitor lymphoblasts in vitro," researchers in the United States report. "ALL cell lines were used to determine if combining mAb 216 with chemotherapeutic drugs would enhance killing and cell lines were used to measure cytotoxicity by mAb 216 with human complement. PROCEDURE: Expression of...
Source: Immunotherapy Weekly (2007-04-11)
|
